| Name | Title | Contact Details |
|---|---|---|
Andrew Pipp |
Vice President Information Technology | Profile |
Andrew Pipp |
Chief Information Officer, Security Officer | Profile |
JHP Pharmaceutical is a Parsippany, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rhoads Pharmacy is a Hummelstown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Affordable RX is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Innomar Strategies, a part of AmerisourceBergen, is Canada`s leading patient support provider for specialty pharmaceuticals. We deliver end-to-end support solutions to improve product access, increase supply chain efficiency and enhance patient care. Strategic consulting, patient assistance programs, nursing and clinical services, and specialty pharmacy and logistics are just a few of our key areas of specialization. We partner closely with manufacturers, healthcare providers, pharmacies and payers to ensure patients have consistent and reliable access to specialty medication. With our integrated approach and commitment to best-in-class care, Innomar Strategies ensures patients are supported throughout their treatment journey every step of the way.
Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.